Overview
Nattokinase is a serine protease enzyme extracted from natto, a traditional Japanese fermented soybean food. Produced by Bacillus subtilis during fermentation, this supplement has garnered significant attention in the cardiovascular health space as a natural alternative or complement to conventional anticoagulant therapies. Rather than acting as a simple blood thinner, nattokinase directly targets the fibrin that forms the structural foundation of blood clots, making it a unique compound for supporting healthy blood flow and cardiovascular function.
The supplement is taken orally and is available in standardized extract forms, typically dosed between 2,000 and 4,000 fibrinolytic units (FU) daily. While most research has concentrated on heart and vascular health, nattokinase has been investigated for numerous other health outcomes—with varying levels of evidence—ranging from cognitive function to joint health to metabolic markers.
This comprehensive guide examines nattokinase's mechanism of action, reviews the evidence for its purported benefits, outlines appropriate dosing protocols, discusses side effects and safety considerations, and provides practical information for those considering supplementation.
How It Works: Mechanism of Action
Nattokinase exerts its primary effects through a remarkably elegant mechanism that directly targets the protein architecture of blood clots. Unlike anticoagulants that prevent clot formation, nattokinase actively dissolves existing clots by cleaving fibrin—the fibrous protein scaffold that gives blood clots their structural integrity.
The enzyme accomplishes this through several complementary pathways:
Fibrinolytic Activity
The most direct mechanism involves nattokinase's ability to mimic and enhance the body's endogenous fibrinolytic system. It directly degrades plasminogen activator inhibitor-1 (PAI-1), a protein that normally suppresses clot dissolution. By reducing PAI-1 levels, nattokinase increases circulating tissue plasminogen activator (tPA) activity, which amplifies the body's natural ability to dissolve fibrin clots through plasmin-mediated mechanisms.
Blood Pressure Regulation
Beyond its clot-busting properties, nattokinase demonstrates modest ACE-inhibitory activity. This means it helps decrease angiotensin II-mediated vasoconstriction—the process by which blood vessels narrow and increase blood pressure. While this secondary mechanism is less potent than dedicated ACE inhibitors, it contributes meaningfully to blood pressure reduction in some users.
Evidence by Health Goal
The scientific literature on nattokinase spans multiple health domains. Below is an evidence-based review organized by health outcome, with each rated according to the strength of existing human clinical evidence.
Heart Health (Tier 3 — Probable Efficacy)
Nattokinase shows the strongest evidence base for cardiovascular support, though effect sizes remain modest and inconsistent.
Blood Pressure Reduction
Multiple randomized controlled trials document systolic blood pressure reductions of approximately 5.55 mmHg and diastolic reductions of 2.84 mmHg versus placebo over 8-week interventions (n=86). A meta-analysis of six RCTs involving 546 total participants found nattokinase reduced systolic pressure by 3.45 mmHg and diastolic by 2.32 mmHg.
Renin Activity and Hemostasis
In hypertensive subjects, nattokinase administration decreased plasma renin activity by 1.17 ng/mL/h compared to control, supporting its blood pressure-lowering effects. The enzyme also consistently prolongs clotting times as measured by collagen-epinephrine closure time, prothrombin time, and activated partial thromboplastin time—confirming its antithrombotic activity in vivo.
Important Limitation
A large, rigorous human RCT found nattokinase had null effects on subclinical atherosclerosis progression, suggesting benefits may be limited to blood pressure and hemostatic markers rather than preventing advanced vascular disease.
Longevity (Tier 3 — Probable Efficacy)
Nattokinase shows probable efficacy for longevity-related cardiovascular outcomes, though evidence of actual lifespan extension remains absent. The blood pressure and vascular inflammation reductions documented in human trials suggest potential longevity benefits through cardiovascular risk reduction, but these studies have been limited to small-to-moderate sample sizes and relatively short intervention periods.
Fat Loss (Tier 2 — Limited Evidence)
Nattokinase has not been proven effective for fat loss in humans. One human RCT (n=80) examined a multi-ingredient formula containing nattokinase and found reduced fasting insulin by 3.07 μIU/mL and improved HOMA-IR (insulin resistance marker) by 0.85 over 12 weeks—but fasting glucose did not decrease, and this was a combination product rather than nattokinase monotherapy.
Animal studies in mice on high-fat diet models show more promising results: nattokinase-enriched fermentation broth combined with aerobic exercise reduced body weight gain, decreased serum triglycerides and LDL cholesterol, and increased HDL. These effects were accompanied by downregulation of lipid synthesis genes (ACC1, FAS) and upregulation of lipid catabolism genes (AdipoQ, ATGL). However, human efficacy remains unproven.
Injury Recovery (Tier 2 — Limited Evidence)
Nattokinase shows plausible promise for injury recovery through anti-inflammatory and thrombolytic mechanisms, though human evidence is minimal.
In animal models of ischemic stroke, nattokinase dose-dependently reduced infarction volume and improved neurological symptoms at doses of 5,000–20,000 FU/kg administered orally for 7 days prior to injury. In rat neuronal oxygen-glucose deprivation/reperfusion models (simulating stroke damage), nattokinase countered cell death by modulating autophagy, apoptosis, and endoplasmic reticulum stress pathways. These protective effects were blocked by serine endopeptidase inhibitors, confirming the enzymatic mechanism was responsible.
Human efficacy evidence is limited to a single RCT focused on stroke recovery with results not fully detailed in available abstracts.
Cognition (Tier 2 — Limited Evidence)
Nattokinase shows promise for cognition in animal models through blood flow improvement and potential amyloid degradation mechanisms, but human efficacy remains unproven.
A human RCT (n=88 per-protocol) administering nattokinase at 8,000 FU/day for 6 months found no significant improvement in overall Montreal Cognitive Assessment scores versus placebo (mean difference 0.038, 95% CI -1.109 to 1.163, p=0.948). Post-hoc analysis revealed only modest visuospatial function improvement (p=0.024, with 0.35 odds ratio for decline risk), which may represent chance findings given the lack of improvement in the primary outcome.
Animal studies show nattokinase dose-dependently reduced infarction volume and improved neurological symptoms in cerebral ischemia models, with decreased proinflammatory cytokines and reactive oxygen species in infarcted brain tissue.
Anti-Inflammation (Tier 2 — Limited Evidence)
Nattokinase demonstrates anti-inflammatory effects in animal models through multiple mechanisms. In rats with focal cerebral ischemia, nattokinase at 130 mg/kg dose-dependently reduced infarct volume through Nrf2-mediated antioxidant activity. In transient ischemia models, nattokinase at 5,000–20,000 FU/kg reduced proinflammatory cytokine levels and decreased reactive oxygen species in infarcted brain tissue, with effects blocked by serine protease inhibitors.
However, a large human RCT found no significant effects on cardiovascular biomarkers despite documented blood pressure reductions, suggesting anti-inflammatory benefits may be modest or indirect.
Gut Health (Tier 2 — Limited Evidence)
Nattokinase shows plausible benefits for gut health through microbiota modulation and anti-inflammatory effects in multiple animal models, though human evidence is limited to one case series.
In mice with high-fat diet and carrageenan-induced thrombosis, nattokinase supplementation decreased the Firmicutes/Bacteroidetes ratio, reduced harmful Shigella, and increased beneficial Lactobacillus and Bacteroides. A recombinant E. coli Nissle 1917 expressing nattokinase significantly better alleviated DSS-induced colitis in mice compared to control strains, with increased colon length and downregulated pro-inflammatory cytokines IL-6 and TNF-α.
Human efficacy remains unproven.
Liver Health (Tier 2 — Limited Evidence)
Nattokinase shows emerging potential for liver health primarily through indirect mechanisms such as lipid reduction and antioxidant effects, but direct evidence of liver-specific efficacy in humans is absent.
One human RCT (n=113) found nattokinase-monascus showed no significant differences in liver function tests versus placebo over 120 days. Animal studies demonstrate more promise: nattokinase improved liver function tests and reduced serum ammonia levels in rats exposed to BPA and gamma radiation via Nrf2/HO-1 pathway activation.
Skin & Hair (Tier 2 — Limited Evidence)
Nattokinase has not been proven effective for skin or hair health as primary outcomes. One small human RCT (n=9) found a single dose of nattokinase (2,000 FU) accelerated skin temperature recovery after cold water immersion in healthy men—with faster recovery in the middle finger, palm, and back of the right hand (p<0.05)—but this represents a peripheral circulatory response rather than a direct skin or hair health benefit.
An 8-week supplementation study (n=50) showed nattokinase prolonged collagen-epinephrine closure time and activated partial thromboplastin time in hypercholesterolemic subjects, indicating altered hemostasis but not skin or hair outcomes.
Hormonal Balance (Tier 2 — Limited Evidence)
Nattokinase has been studied for hormonal health primarily in animal models, showing potential effects on insulin secretion and glucose tolerance. In pancreatectomized diabetic rats, an AGM formula containing nattokinase improved insulin tolerance and insulin secretion capacity with dose-dependent improvements in glucose tolerance. A GLP-1/nattokinase fusion polypeptide reduced fasting blood glucose to near-normal levels in type 2 diabetic mice after 15 days.
No human clinical trials exist to prove efficacy for hormonal goals in humans.
Muscle Growth (Tier 1 — No Evidence)
Nattokinase has not been studied for muscle growth in humans or animals. All available evidence focuses on cardiovascular, thrombolytic, neuroprotective, and metabolic effects; zero studies demonstrate efficacy for muscle hypertrophy or strength gains.
Joint Health (Tier 1 — No Evidence)
Nattokinase has not been studied for joint health in humans. The only available human evidence consists of RCTs focused on myocardial infarction and animal studies examining diabetic retinopathy—neither addresses joint health efficacy.
Mood & Stress (Tier 1 — No Evidence)
Nattokinase has not been studied for mood or stress outcomes in humans. One animal study reported a nattokinase-containing inulin gel "alleviated anxiety and depression symptoms" via the microbiota-gut-brain axis, but nattokinase was one component in a multi-component formulation with Prussian blue nanozymes and inulin gel, making attribution to nattokinase alone impossible.
Energy (Tier 1 — No Evidence)
Nattokinase has not been studied for energy as a primary outcome in humans. One case series (n=5) reported fatigue improvement as part of multi-symptom response to Post-Spike Syndrome treatment including nattokinase plus ivermectin and microbiome restoration, but the isolated effect of nattokinase on fatigue was not quantified.
Immune Support (Tier 1 — No Evidence)
Nattokinase has not been studied for immune function in humans. Animal models suggest potential immunomodulatory pathways—including enhanced CAR-T cell infiltration in tumor models when combined with targeted immunotherapy—but no human trials demonstrate efficacy for immune health.
Sexual Health (Tier 1 — No Evidence & Safety Concern)
No evidence supports nattokinase for sexual health. The only available study documents a severe adverse event: one patient self-injected nattokinase intravascularly for Peyronie's disease and developed vascular necrosis requiring amputation. This case demonstrates serious safety risks of inappropriate administration rather than therapeutic benefit.